Effect of comorbidity on mortality in multiple sclerosis

Ruth Ann Marrie, Lawrence Elliott, James Marriott, Michael Cossoy, James Blanchard, Stella Leung, Nancy Yu, Ruth Ann Marrie, Lawrence Elliott, James Marriott, Michael Cossoy, James Blanchard, Stella Leung, Nancy Yu

Abstract

Objective: We aimed to compare survival in the multiple sclerosis (MS) population with a matched cohort from the general population, and to evaluate the association of comorbidity with survival in both populations.

Methods: Using population-based administrative data, we identified 5,797 persons with MS and 28,807 controls matched on sex, year of birth, and region. We estimated annual mortality rates. Using Cox proportional hazards regression, we evaluated the association between comorbidity status and mortality, stratifying by birth cohort, and adjusting for sex, socioeconomic status, and region. We compared causes of death between populations.

Results: Median survival from birth in the MS population was 75.9 years vs 83.4 years in the matched population. MS was associated with a 2-fold increased risk of death (adjusted hazard ratio 2.40; 95% confidence interval: 2.24-2.58). Several comorbidities were associated with increased hazard of death in both populations, including diabetes, ischemic heart disease, depression, anxiety, and chronic lung disease. The magnitude of the associations of mortality with chronic lung disease, diabetes, hypertension, and ischemic heart disease was lower in the MS population than the matched population. The most common causes of death in the MS population were diseases of the nervous system and diseases of the circulatory system. Mortality rates due to infectious diseases and diseases of the respiratory system were higher in the MS population.

Conclusion: In the MS population, survival remained shorter than expected. Within the MS population, comorbidity was associated with increased mortality risk. However, comorbidity did not preferentially increase mortality risk in the MS population as compared with controls.

© 2015 American Academy of Neurology.

References

    1. Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology 1994;13:1–7.
    1. Beck CA, Metz LM, Svenson LW, Patten SB. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler 2005;11:516–519.
    1. Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Mortality in patients with multiple sclerosis. Neurology 2013;81:184–192.
    1. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844–850.
    1. Llorca J, Guerrero-Alonso P, Prieto-Salceda D. Mortality trends of multiple sclerosis in Spain, 1951–1997: an age-period-cohort analysis. Neuroepidemiology 2005;24:129–134.
    1. Ekestern E, Lebhert G. Mortality from multiple sclerosis in Austria 1970–2001: dynamics, trends, and prospects. Eur J Neurol 2004;11:511–520.
    1. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991–994.
    1. Goodin DS, Corwin M, Kaufman D, et al. Causes of death among commercially insured multiple sclerosis patients in the United States. PLoS One 2014;9:e105207.
    1. Lalmohamed A, Bazelier MT, Van Staa TP, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. Eur J Neurol 2012;19:1007–1014.
    1. Krokki O, Bloigu R, Ansakorpi H, Reunanen M, Remes AM. Neurological comorbidity and survival in multiple sclerosis. Mult Scler Relat Disord 2014;3:72–77.
    1. Health Information Management Branch. Population Report. Winnipeg: Manitoba Health and Healthy Living; 2008.
    1. Statistics Canada. Vital Statistics Death Database [online]. Available at: . Accessed March 6, 2011.
    1. Marrie RA, Yu N, Blanchard JF, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010;74:465–471.
    1. Marrie RA, Horwitz RI, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009;72:117–124.
    1. Dallmeijer AJ, Beckerman H, de Groot V, van de Port IGL, Lankhorst GJ, Dekker J. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehabil Med 2009;41:322–326.
    1. Warren SA, Turpin KV, Pohar SL, Jones CA, Warren KG. Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care 2009;11:6–16.
    1. Marrie RA, Yu B, Leung S, et al. Rising prevalence of vascular comorbidities in MS: validation of administrative definitions for diabetes, hypertension, hyperlipidemia. Mult Scler 2012;18:1310–1319.
    1. Marrie RA, Yu BN, Leung S, et al. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology 2013;40:85–92.
    1. Marrie RA, Fisk JD, Yu BN, et al. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol 2013;13:16.
    1. Marrie RA, Yu BN, Leung S, et al. Prevalence and incidence of ischemic heart disease in multiple sclerosis: a population-based validation study. Mult Scler Relat Disord 2013;2:355–361.
    1. Marrie RA, Yu BN, Leung S, et al. The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: a population-based study. Mult Scler Relat Disord 2012;1:162–167.
    1. Lamarca R, Alonso J, Gómez G, Muñoz Á. Left-truncated data with age as time scale: an alternative for survival analysis in the elderly population. J Gerontol A Biol Sci Med Sci 1998;53:M337–M343.
    1. Gross S, Lai T. Nonparametric estimation and regression analysis with left-truncated and right-censored data. J Am Stat Assoc 1996;91:1166–1180.
    1. Allison PD. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Press; 1995.
    1. Rothman KJ, Greenland S, editors. Modern Epidemiology, 2nd ed Philadelphia: Lippincott Williams & Wilkins; 1998.
    1. Sjölander A, Greenland S. Ignoring the matching variables in cohort studies: when is it valid and why? Stat Med 2013;32:4696–4708.
    1. Ford HL, Gerry E, Johnson M, Williams R. A prospective study of the incidence, prevalence and mortality of multiple sclerosis in Leeds. J Neurol 2002;249:260–265.
    1. Patzold U, Pocklington PR. Course of multiple sclerosis: first results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol Scand 1982;65:248–266.
    1. Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005;32:1013–1019.
    1. van Dooren FE, Nefs G, Schram MT, Verhey FR, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 2013;8:e57058.
    1. Mykletun A, Bjerkeset O, Dewey M, Prince M, Overland S, Stewart R. Anxiety, depression, and cause-specific mortality: the HUNT Study. Psychosom Med 2007;69:323–331.
    1. Roness A, Mykletun A, Dahl AA. Help-seeking behaviour in patients with anxiety disorder and depression. Acta Psychiatr Scand 2005;111:51–58.
    1. Marrie RA, Elliott L, Marriott J, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology 2015;84:350–358.
    1. Higashi T, Wenger NS, Adams JL, et al. Relationship between number of medical conditions and quality of care. N Engl J Med 2007;356:2496–2504.
    1. Larsen JP, Kvale G, Aarli JA. Multiple sclerosis and mortality statistics. Acta Neurol Scand 1985;71:237–241.
    1. O'Malley F, Dean G, Elian M. Multiple sclerosis and motor neurone disease: survival and how certified after death. J Epidemiol Community Health 1987;41:14–17.
    1. Ragonese P, Salemi G, Aridon P, et al. Accuracy of death certificates for motor neuron disease and multiple sclerosis in the province of Palermo in southern Italy. Neuroepidemiology 2002;21:148–152.
    1. Riudavets MA, Colegial C, Rubio A, Fowler D, Pardo C, Troncoso JC. Causes of unexpected death in patients with multiple sclerosis: a forensic study of 50 cases. Am J Forensic Med Pathol 2005;26:244–249.
    1. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193–1196.
    1. Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology 2006;26:102–107.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera